Approved as EGRIFTA (tesamorelin) for reduction of excess visceral adipose tissue in HIV-associated lipodystrophy.
Tesamorelin is the full 44-amino-acid sequence of human growth hormone-releasing hormone with an N-terminal hexenoyl modification that confers resistance to DPP-IV-mediated degradation, extending its ...
Tesamorelin is the full 44-amino-acid sequence of human growth hormone-releasing hormone with an N-terminal hexenoyl modification that confers resistance to DPP-IV-mediated degradation, extending its half-life relative to native GHRH. It binds the pituitary GHRH receptor to stimulate endogenous GH/IGF-1 axis activity, and has been studied specifically, and successfully in pivotal human trials, for reducing visceral adipose tissue.
AIDS · 2021
Pooled analysis found tesamorelin increased visceral and subcutaneous adipose tissue density (a marker of healthier fat composition) over 26 weeks, independent of the amount of fat lost.
View Source →PLoS One · 2015
Pooled analysis of two Phase 3 trials found baseline metabolic syndrome, elevated triglycerides, and other factors predicted greater visceral fat reduction, with tesamorelin patients roughly 4x more likely to achieve a healthy visceral fat threshold than placebo.
View Source →Journal of Acquired Immune Deficiency Syndromes · 2010
In 404 HIV-infected patients, 6-month tesamorelin treatment significantly reduced visceral adipose tissue, waist circumference, and waist-hip ratio versus placebo; a 12-month extension sustained roughly 18% VAT reduction, which reversed after discontinuation.
View Source →